Versant Venture Management, LLC
Q1 2025 13F Holdings
- Locationsan francisco, CA
- Num holdings
7
- Value ($000)
$60,209
- Date Filed05/07/2025
- Form type13F-HR
- CIK0001560009
- All SEC filings
- NoteHoldings aggregated across “other managers” listed in original SEC filing, see here for detailed holdings broken out by other managers
Compare Q1 2025 toSelect Quarter
Issuer Name | Class | CUSIP | VALUE | % | Shares | Principal | Option Type |
|---|---|---|---|---|---|---|---|
GLUE Monte Rosa Therapeutics, Inc. | COMMON STOCK | 61225M102 | $26.23M | 44 % | 5,652,922 | ||
CRISPR Therapeutics AG | COMMON SHARES | H17182108 | $16.97M | 28 % | 498,558 | ||
CTNM Contineum Therapeutics, Inc. | COMMON STOCK | 21217B100 | $6.41M | 11 % | 918,163 | ||
SKYE Skye Bioscience, Inc. | COMMON STOCK | 83086J200 | $3.19M | 5 % | 2,007,704 | ||
RPTX Repare Therapeutics, Inc. | COMMON STOCK | 760273102 | $2.61M | 4 % | 2,646,657 | ||
Tempest Therapeutics, Inc. | COMMON STOCK | 87978U207 | $2.59M | 4 % | 3,507,055 | ||
ADVM Adverum Biotechnologies, Inc. | COMMON STOCK | 00773U108 | $2.21M | 4 % | 506,821 |
Rows Per Page
10
- 10
- 50
- 100